TCGA-EW-A1PF-01A-11R-A144-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 15
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.500
- ANGIOGENESIS+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- APICAL_JUNCTION+0.420
- UV_RESPONSE_DN+0.380
- TGF_BETA_SIGNALING+0.340
- ESTROGEN_RESPONSE_EARLY+0.300
- MYOGENESIS+0.300
- COAGULATION+0.270
- APICAL_SURFACE+0.240
Top 10 suppressed
- E2F_TARGETS-0.540
- MYC_TARGETS_V1-0.450
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V2-0.320
- DNA_REPAIR-0.310
- SPERMATOGENESIS-0.270
- PANCREAS_BETA_CELLS-0.260
- INTERFERON_ALPHA_RESPONSE-0.180
- MTORC1_SIGNALING-0.170
- OXIDATIVE_PHOSPHORYLATION-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.881 |
| 2 | 6b548699-9440-4acc-86b6-faeb367454a2 | — | — | 0.862 |
| 3 | TCGA-FD-A5BZ-01A-11R-A28M-07 | — | — | 0.858 |
| 4 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.856 |
| 5 | TCGA-AO-A0JF-01A-11R-A056-07 | — | A | 0.856 |
| 6 | 22620634-aa34-4cb5-a37f-5a7b0c47cd0e | — | — | 0.854 |
| 7 | TCGA-D8-A146-01A-31R-A115-07 | — | A | 0.848 |
| 8 | TCGA-DK-A2HX-01A-12R-A18C-07 | — | — | 0.846 |
| 9 | JHH2_LIVER | HCC | — | 0.842 |
| 10 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.420 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |